Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 204, Issue 3, Pages 415-418Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jir282
Keywords
-
Categories
Funding
- Bristol-Myers Squibb
- Gilead Sciences
- Novartis
- Roche
- Merck
- Foundation for Liver Research (SLO), Rotterdam, the Netherlands
Ask authors/readers for more resources
Nucleos(t)ide analogues strongly inhibit viral replication in chronic hepatitis B (CHB) infection, but knowledge of their long-term effect on serum hepatitis B surface antigen (HBsAg) levels and HBsAg loss is lacking. Seventy-five CHB patients with virological response (VR) to ETV or TDF were included. HBsAg decline 2 years after VR was most pronounced in HBeAg-positive patients. Age, alanine aminotransferase, and HBeAg loss were associated with HBsAg decline in HBeAg-positive patients. Predicted median time to HBsAg loss was 36 years for HBeAg-positive and 39 years for HBeAg-negative patients. Thus, most patients treated with ETV and TDF will probably need decades of therapy to achieve HBsAg loss.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available